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➢ Phenylketonuria (PKU) was discovered by Dr.
Asbjørn Følling in the 1930s.
➢ A concerned mother brought in her two children to
Dr. Følling after noticing a musty smell in their
urine and mental decline during early childhood.
➢ Dr. Følling observed an unusually high level of
phenylpyruvate in their urine, and concluded that
the children could not properly metabolize the
amino acid phenylalanine.
Dr. Asbjørn Følling
The discovery of phenylketonuria: The story of a young 
couple, two retarded children, and a scientist. 
Digital image retrieved Oct 28, 2019 from 
https://doi.org/10.1542/peds.105.1.89
➢ PKU is most prevalent in Turkey (1 in 2,500), as
well as in Ireland, Scotland, and among Yemenite
Jews (1 in 5,000)
➢ Mutation in the Phenylalanine Hydroxylase gene
➢ Autosomal recessive allele in chromosome 12
Phenylketonuria Incidence by country.  
Digital image retrieved Oct 14, 2019 from 
https://bmjopen.bmj.com/content/9/8/e031474#F3








Digital image retrieved Jan 12, 2020  from
https://www.geneticsupport.org/genetics-101/inheritance-patterns/autosomal-recessive/
Autosomal Recessive Inheritance - Genetics 
Video file retrieved Jan 12, 2020 from 
https://www.youtube.com/watch?time_continue=4&v=Nv6qUsKYodA&feature=emb_logo
➢ Inability to properly metabolize the amino acid phenylalanine (Phe) to the amino
acid tyrosine (Tyr) due to mutations in PAH.
➢ Both Phe and Tyr are essential for protein synthesis
- Phe and Tyr are present in eggs, soybeans, meats, and other foods
➢ In PKU, there is a buildup of Phe, which disrupts brain function
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➢ BH4 is a coenzyme/cofactor that is necessary for
PAH to convert Phe to Tyr.
Tetrahydropterin
(BH4)
Structures of phenylalanine and tyrosine




Phe metabolism in humans










➢ PKU is detected via a newborn heel prick test
- Only requires 4 drops of blood
- Detects Phe elevation in blood
➢ If elevated Phe level is detected, newborn is 
treated immediately to avoid symptoms
Newborn blood spot screening
Digital image retrieved Oct 14, 2019 from 
https://www.nhs.uk/conditions/pregnancy-and-baby/newborn-blood-spot-faqs/
Diagnosis
Symptoms do not show up in newborns but develop 
within a few months in the absence of treatment
Severe symptoms
➢ Progressive intellectual disability





➢ Musty odor to urine
➢ Increased irritability which leads to
loss of sleep
Symptoms
➢ PKU does not affect life expectancy, with or without treatment
➢ Clinical severity depends on the degree of PAH deficiency
Prognosis
➢ Non-classical PKU individuals may not need treatment
Table above reproduced without modifications and retrieved Nov 15, 2019
https://www.ccrc.uga.edu/~steet/bcmb8160/lectures/PKU%20lecture.pdf
Digital image retrieved Oct 09, 2019 from 
https://slideplayer.com/slide/7451969/
➢ The drug Kuvan® mimics BH4 which is a coenzyme/cofactor that assists PAH
in the breakdown of Phe to Tyr.
➢ Kuvan® is not suitable for all patients who suffer PKU symptoms.
➢ How does Kuvan work?
Therapy 
Mechanism of action of Kuvan
Video file retrieved Feb 01, 2020 from
https://www.youtube.com/watch?v=62v-TuEBCFo
Therapy
➢ Treatment consists of a
closely monitored diet
➢ Refrain from foods
containing Phe and/or
limit protein intake




International PKU awareness day
Digital image retrieved Nov 13, 2019 from
https://www.nipd.com/articles/blog/international-phenylketonuria-awareness-day/
➢ Careful dietary restriction is especially important for pregnant individuals
with PKU or even non-PKU hyperphenylalanemia
➢ When there is a buildup of Phe in a pregnant mother, increased levels of
Phe will cross the placenta, which has a detrimental effect on the
developing fetus.
- Craniofacial abnormalities, congenital heart disease, mental retardation,
growth retardation
- Fetus can display symptoms without having the PAH mutation
Importance of diet
There are multiple agencies that support those affected:
➢National Organization for Rare Diseases (NORD)
➢ PKU & Me program (PKU.com)
➢ The National PKU Alliance (npkua.org)
○ Dedicated to spreading awareness, and raising money for
researching a cure.
○ Functions out of many clinics in Ohio including
the Nationwide Children's Hospital in Columbus.
Digital image retrieved Oct 14, 2019 from 
https://www.pku.com/community-and-support/pku-and-me
Available support
Digital image retrieved Oct 16, 2019 from 
https://rarediseases.org/
Digital image retrieved Oct 16, 2019 from 
https://www.npkua.org/
Name Project role
Tim Barley (Illustration) Occurrence, Provenance, and Genetics
Maia Bates Diagnosis and Symptoms
Jacob Brent Additional Support
I. Rosemary Erwin (Text) Therapy
Emma Montgomery History
Cameron Spangler Prognosis
Amanda Thornton Biochemical Features
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